Ascletis Pharma (HKG:1672) said its phase 1B multiple ascending dose study for its ASC30 tablets for obesity showed positive topline results, according to a Wednesday filing with the Hong Kong bourse.
The drug showed a favorable safety profile, with gastrointestinal-related adverse events mild and short-lived, the filing said.
Trial enrollees did not show serious adverse events, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.